An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys)

Medicine (United States)

Volumn 95, Issue 14, 2016, Pages

  Chon, Young Eun ^a   Kim, Dong Joon ^d,h   Kim, Sang Gyune ^g   Kim, In Hee ⁱ   Bae, Si Hyun ^b   Hwang, Seong Gyu ^j   Heo, Jeong ^k   Jang, Jeong Won ^b   Lee, Byung Seok ^l   Kim, Hyung Joon ^c   Jun, Dae Won ^a   Kim, Kang Mo ^e   Chung, Woo Jin ^m   Choi, Moon Seok ^f   Jang, Jae Young ^g   Yim, Hyung Joon ⁿ   Tak, Won Young ^l   Yoon, Ki Tae ^k   Park, Jun Yong ^a   Han, Kwang Hyub ^a   Suk, Ki Tae ^h   Lee, Hyun Woong ^c   Jang, Byoung Kuk ^m   Ahn, Sang Hoon ^a   more..

^a Yonsei University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Hanyang University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Sungkyunkwan University   (South Korea)

^g Soonchunhyang University College of Medicine   (South Korea)

^h Hallym University College of Medicine   (South Korea)

ⁱ Chonbuk National University Medical School   (South Korea)

^j CHA University   (South Korea)

^k Pusan National University School of Medicine   (South Korea)

^l Chungnam National University College of Medicine   (South Korea)

^m Keimyung University   (South Korea)

ⁿ Korea University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS B; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; INVESTIGATIVE PROCEDURES; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; HEPATITIS B, CHRONIC; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 84964612656     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003026     Document Type: Article

References (32)

1. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
3. Jung KS, Kim SU, Song K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 2015;62:1757-1766.
4. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.
5. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459-467.
6. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int. 2014;34(Suppl 1):112-119.
7. Kwon JH, Kim YS, Kim SG, et al. The efficacy and safety of peginterferon-Alpha-2a in Korean patients with chronic hepatitis B: a multicenter study conducted in a real clinical setting. Gut Liver. 2013;7:197-205.
8. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298-305.
9. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-2695.
10. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351: 1206-1217.
11. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591-1599.
12. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561.
13. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-Alfa. Gastroenterology. 2009;137:2002-2009.
14. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123-129.
15. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136:2169-2179e2161-2164.
16. Ratnam D, Dev A, Nguyen T, et al. Efficacy and tolerability of pegylated interferon-Alpha-2a in chronic hepatitis B: a multicenter clinical experience. J Gastroenterol Hepatol. 2012;27:1447-1453.
17. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011;54:443-451.
18. Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264-1271.
19. Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012;57:508-514.
20. Petersen J, Heyne R, Mauss S, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany. Dig Dis Sci. 2015.
21. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-2455.
22. Ahn SS, Chon YE, Kim BK, et al. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. Clin Mol Hepatol. 2014;20:261-266.
23. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56:699-705.
24. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454-461.
25. Goulis I, Karatapanis S, Akriviadis E, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int. 2015;35:1540-1548.
26. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56:1006-1011.
27. Yang HC, Chen CL, Shen YC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology. 2013;57:934-943.
28. Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg() chronic hepatitis than genotype C. Hepatology. 2002;36:1425-1430.
29. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251-1257.
30. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatol-ogy. 2013;58:872-880.
31. Iannazzo S, Coco B, Brunetto MR, et al. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-Alpha2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. Antivir Ther. 2013;18:623-633.
32. Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46:388-394.